Praluent Continues to Show Benefits Since Approval

Video

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

Jay Edelberg, MD, PhD, and Sheldon Koenig, from Sanofi, discussed the progress made in less than 18 months during the American Heart Association's Scientific Sessions in New Orleans, LA. Edelberg called the approval process a "great journey," and noted that since its approval, and even during the clinical trials, there was clear evidence of helping at risk patients lower their cholesterol levels to considerably lower levels.

Despite the success, Koenig said there have been challenges, including overcoming utilization magangement criteria. However, since its approval providers have found ways to overcome those challenges to get patients the care they need.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 5 cardiovascular experts
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
© 2024 MJH Life Sciences

All rights reserved.